Medical News

August 13, 2004 — Research and Markets announces the addition of this new report entitled “Progress on Novel Strategies & Drugs” to its offerings.

This issue of “BSG Cancer Highlights” presents a progress analysis on what has been identified as new and interesting strategies for the treatment of cancer. Presentation of industry related achievements on hypoxia induced prodrugs, aurora kinase inhibitors, IGF-R1 antagonists, apoptosis inducing biological drugs, new taxane entities, mitotic inhibitors, mTOR and cell adhesion blockers have been studied as well as the drug target situation. Additionally, progress on PEG formulations of cancer drugs has been studied.

The prodrugs are designed to be non-toxic until selectively activated by bioreduction in hypoxic cells to selectively inhibit their targets, e.g. topoisomerase II. Aurora kinases are down regulating the tumor suppressor p53. Inhibitors of the Aurora kinase family therefore have potential to block growth of all tumor types. Researchers has reported that IGF-1R is an attractive target for development of therapeutics since it can make tumor cells more sensitive to conventional chemotherapy or other anticancer agents. Some biological drug candidates have been found to be involved as a growth inhibitors and promoters of cell death in the natural control of excessive and/or abnormal proliferation. Furthermore, novel analogs of taxotere have been shown inhibit the growth of both paclitaxel and docetaxel sensitive and resistant tumor cell lines. Clinical data is now emerging.

Mitotic kinesins play essential roles during all phases of mitosis. These enzymes are “molecular motors” that transform energy released by hydrolysis of ATP into mechanical force. Targeting specific proteins during mitosis is a strategy that is becoming more and more interesting.

Cell adhesion is of outmost importance for tumor growth and spreading as well as the tumor vascular tree. Utilizing drugs targeting cell adhesion molecules such as cadherins promising results have been obtained. PEG-technology of cancer drugs has now reached all the way into phase III trials.

Many of these drugs have entered clinical trials and results are emerging. Results from these studies suggest that continuing efforts will be invested in these drugs. Patents related to these drugs and targets have been studied and relevant patents are described.

Companies such as Wyeth, Bristol-Myers Squibb, Merck Co. Inc, GlaxoSmithKline, AstraZeneca, Novartis, Schering-Plough, Pfizer Aventis, Genentech, Immunex, Vertex Pharmaceutical, Callisto Pharmaceuticals, Procyon BioPharma, Taxolog Inc, PharmaMar, Adherex Technologies, Novacea, Inc, KuDOS Pharmaceuticals and several others are involved in developing new drugs utilizing these strategies.

For a complete index of this report click on http://www.researchandmarkets.com/reports/220873

About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute thousands of major research publications from the world’s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com

August 13, 2004 — Research and Markets announces the addition of this new report entitled “Progress on Novel Strategies & Drugs” to its offerings.

This issue of “BSG Cancer Highlights” presents a progress analysis on what has been identified as new and interesting strategies for the treatment of cancer. Presentation of industry related achievements on hypoxia induced prodrugs, aurora kinase inhibitors, IGF-R1 antagonists, apoptosis inducing biological drugs, new taxane entities, mitotic inhibitors, mTOR and cell adhesion blockers have been studied as well as the drug target situation. Additionally, progress on PEG formulations of cancer drugs has been studied.

The prodrugs are designed to be non-toxic until selectively activated by bioreduction in hypoxic cells to selectively inhibit their targets, e.g. topoisomerase II. Aurora kinases are down regulating the tumor suppressor p53. Inhibitors of the Aurora kinase family therefore have potential to block growth of all tumor types. Researchers has reported that IGF-1R is an attractive target for development of therapeutics since it can make tumor cells more sensitive to conventional chemotherapy or other anticancer agents. Some biological drug candidates have been found to be involved as a growth inhibitors and promoters of cell death in the natural control of excessive and/or abnormal proliferation. Furthermore, novel analogs of taxotere have been shown inhibit the growth of both paclitaxel and docetaxel sensitive and resistant tumor cell lines. Clinical data is now emerging.

Mitotic kinesins play essential roles during all phases of mitosis. These enzymes are “molecular motors” that transform energy released by hydrolysis of ATP into mechanical force. Targeting specific proteins during mitosis is a strategy that is becoming more and more interesting.

Cell adhesion is of outmost importance for tumor growth and spreading as well as the tumor vascular tree. Utilizing drugs targeting cell adhesion molecules such as cadherins promising results have been obtained. PEG-technology of cancer drugs has now reached all the way into phase III trials.

Many of these drugs have entered clinical trials and results are emerging. Results from these studies suggest that continuing efforts will be invested in these drugs. Patents related to these drugs and targets have been studied and relevant patents are described.

Companies such as Wyeth, Bristol-Myers Squibb, Merck Co. Inc, GlaxoSmithKline, AstraZeneca, Novartis, Schering-Plough, Pfizer Aventis, Genentech, Immunex, Vertex Pharmaceutical, Callisto Pharmaceuticals, Procyon BioPharma, Taxolog Inc, PharmaMar, Adherex Technologies, Novacea, Inc, KuDOS Pharmaceuticals and several others are involved in developing new drugs utilizing these strategies.

For a complete index of this report click on http://www.researchandmarkets.com/reports/220873

About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute thousands of major research publications from the world’s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com